{
  "id": 11404412,
  "title": "Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront",
  "url": "https://urgent.news/2026/10/02/novartis-takes-rights-to-abogens-mrna-t-cell-engager-for-575m-upfront",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T08:55:40.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novartis-takes-rights-to-abogens-mrna-t-cell-engager-for-575m-upfront/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Novartis will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, which is the Chinese biotech's lead asset. Abogen could get up to about $7.2 billion further ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}